These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 27015814)

  • 1. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
    Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
    J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
    Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
    Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720 Exerts Anti-Glioma Effects by Regulating the Glioma Microenvironment Through Increased CXCR4 Internalization by Glioma-Associated Microglia.
    Guo XD; Ji J; Xue TF; Sun YQ; Guo RB; Cheng H; Sun XL
    Front Immunol; 2020; 11():178. PubMed ID: 32194542
    [No Abstract]   [Full Text] [Related]  

  • 4. CXCR4-STAT3 Axis Plays a Role in Tumor Cell Infiltration in an Orthotopic Mouse Glioblastoma Model.
    Han JH; Yoon JS; Chang DY; Cho KG; Lim J; Kim SS; Suh-Kim H
    Mol Cells; 2020 Jun; 43(6):539-550. PubMed ID: 32597394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.
    Gatti M; Pattarozzi A; Bajetto A; Würth R; Daga A; Fiaschi P; Zona G; Florio T; Barbieri F
    Toxicology; 2013 Dec; 314(2-3):209-20. PubMed ID: 24157575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
    Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
    ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
    Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
    Front Immunol; 2021; 12():637053. PubMed ID: 34108959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.
    Goffart N; Kroonen J; Di Valentin E; Dedobbeleer M; Denne A; Martinive P; Rogister B
    Neuro Oncol; 2015 Jan; 17(1):81-94. PubMed ID: 25085362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF as a modulator of the innate immune response in glioblastoma.
    Turkowski K; Brandenburg S; Mueller A; Kremenetskaia I; Bungert AD; Blank A; Felsenstein M; Vajkoczy P
    Glia; 2018 Jan; 66(1):161-174. PubMed ID: 28948650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma.
    Shi Y; Chen C; Yu SZ; Liu Q; Rao J; Zhang HR; Xiao HL; Fu TW; Long H; He ZC; Zhou K; Yao XH; Cui YH; Zhang X; Ping YF; Bian XW
    Clin Cancer Res; 2015 Sep; 21(17):4004-13. PubMed ID: 26023083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.
    Yadav VN; Zamler D; Baker GJ; Kadiyala P; Erdreich-Epstein A; DeCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
    Oncotarget; 2016 Dec; 7(50):83701-83719. PubMed ID: 27863376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
    Benedicto A; Romayor I; Arteta B
    Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
    Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
    Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
    Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
    Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
    Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
    Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
    Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
    J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.